Tag Archives: CAR Engineering

Gilead Reports Innovative Biomarkers Associated with Clinical Outcomes in the Ph2 ZUMA-5 Trial; Carl June Explores Novel Approaches to Improve CAR-T Function; IL-2 Makes a Comeback with OrthoCARs; AACR 2021 Day 3

On the third day of AACR 2021 Week I, key clinical / preclinical updates were reported from Gilead (Kite) and Synthekine, while Carl June presented an overview of CAR-T engineering tools to improve efficacy and safety outcomes. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.